sk&f 99085 has been researched along with Kahler Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bentzen, CL; Chantry, A; Croucher, PI; Edwards, CM; Guyon-Gellin, Y; Mueller, G; Niesor, EJ; Perry, M; Roelofs, AJ; Russell, RG; Van Camp, B; Vanderkerken, K | 1 |
| Ebetino, FH; Edwards, CM; Hulley, PA; Roelofs, AJ; Rogers, MJ; Russell, RG | 1 |
2 other study(ies) available for sk&f 99085 and Kahler Disease
| Article | Year |
|---|---|
Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Topics: Animals; Apoptosis; Bone Density; Bone Resorption; Diphosphonates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Osteoclasts; Paraproteins; Tumor Cells, Cultured | 2007 |
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Diphosphonates; Down-Regulation; Drug Synergism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Multiple Myeloma; Phosphatidylcholines; Protein Prenylation | 2007 |